A5045754253- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- vaccines and immunoinformatics approaches
- Nanoplatforms for cancer theranostics
- Phagocytosis and Immune Regulation
- Immune Cell Function and Interaction
- Cancer Mechanisms and Therapy
- Chromatin Remodeling and Cancer
- Immune cells in cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Peptidase Inhibition and Analysis
Shenyang Pharmaceutical University
2022-2024
Anderson University - South Carolina
2024
Abstract A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety neoantigen-specific...
T cell receptor (TCR)-engineered therapy is a promising potential treatment for solid tumors, with preliminary efficacy demonstrated in clinical trials. However, obtaining clinically effective TCR molecules remains major challenge. We have developed strategy cloning tumor-specific TCRs from long-term surviving patients who responded to immunotherapy. Here, we report the identification of (10F04), which human leukocyte antigen (HLA)-DRA/DRB1*09:01 restricted and papillomavirus type 18 (HPV18) E7
Abstract Cancer genomic studies have identified frequent alterations in components of the SWI/SNF (SWItch/Sucrose Non- Fermenting) chromatin remodeling complex including SMARCA4 and ARID1A . Importantly, clinical reports indicate that -mutant lung cancers respond poorly to immunotherapy dismal prognosis. However, mechanistic basis resistance is unknown. Here, we corroborated findings by using immune-humanized, syngeneic, genetically engineered mouse models cancer harboring deficiency....
<div>Abstract<p>A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety...
<div>Abstract<p>A high rate of recurrence after curative therapy is a major challenge for the management hepatocellular carcinoma (HCC). Currently, no effective adjuvant available to prevent HCC recurrence. We designed personalized neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, used it as treat 10 patients with who had undergone resection or radiofrequency ablation in first stage phase II trial (NCT03067493). The primary outcomes were safety...
Supplementary Figure from Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
Supplementary Figure from Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma
Immunosuppressive tumor microenvironment (ITM), poor immunogenicity and low penetration markedly inhibit the immunotherapy capability. To address these hurdles, we successfully engineered acidity-triggered nanoparticles (NPs) with size-reduction charge-switchable to boost based on indoleamine 2,3-dioxygenase 1 siRNA (IDO1 siRNA) immunogenic cell death (ICD). Sequentially NPs significantly augmented penetrating ability improved cellular uptake via detachment of 2,3-dimethylmaleic anhydride...